Physical Activity Reduces Risk of Rheumatoid Arthritis
New Options for Treatment-Resistant RA
Abx464 Enters Phase 2 Clinical Trials for RA in Europe
Catch Your Breath: Insights into ILD in RA Patients
FDA Approves Upadacitinib for RA
Long-Term Physical Activity Lowers the Risk of RA among Women
Filgotinib Promising for RA
FDA Approves AbbVie’s New Rheumatoid Arthritis Drug
Otilimab Begins Phase 3 Clinical Studies for RA
- 1
- 2
- 3
- …
- 22
- Next Page »